Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
'Patients are Waiting'over 2 years ago
Today’s New Messaging Mix: The State of Pharma Marketing in 2024over 2 years ago
Patient Treatment & Travel: The Need for Stepped-Up Supportover 2 years ago
A Biosimilars Roadmap: Understanding Payer Perceptionsover 2 years ago
Avoiding the Digital Age is Hurting Research Effortsover 2 years ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 2 years ago
Yvonne Greenstreet: Answering the CallAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5